- Home
- NEGG vs AMRN Comparison
NEGG vs AMRN Comparison
Compare NEGG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$54.06
HOLD
Current Price
$13.79
Company Overview
Basic Information| Metric | NEGG | AMRN |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 339.8M |
| IPO Year | 2010 | 1993 |
Fundamental Metrics
Financial Performance| Metric | NEGG | AMRN |
|---|---|---|
| Price | $54.06 | $13.79 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 159.1K | 80.1K |
| Earning Date | 12-01-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,313,127,000.00 | $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.32 | $7.08 |
| 52 Week High | $137.84 | $20.90 |
Technical Indicators
Market Signals| Indicator | NEGG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 32.16 |
| Support Level | $52.61 | $13.64 |
| Resistance Level | $79.60 | $14.49 |
| Average True Range (ATR) | 5.69 | 0.76 |
| MACD | -2.15 | -0.11 |
| Stochastic Oscillator | 5.37 | 11.73 |
Price Performance
Historical Comparison NEGG
AMRN
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.